DARA VCD PROTOKOLÜ

Kaynaklar:

1- Palumbo, A. , Chanan‐Khan, A. , Weisel, K. , Nooka, A.K. , Masszi, T. , Beksac, M. , Spicka, I. , Hungria, V. , Munder, M. , Mateos, M.V. , Mark, T.M. , Qi, M. , Schecter, J. , Amin, H. , Qin, X. , Deraedt, W. , Ahmadi, T. , Spencer, A. & Sonneveld, P. (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. New England Journal of Medicine, 375, 754–766.

2- Spencer, A. , Hungria, V.T.M. , Mateos, M.‐V. , Nooka, A. , Estell, J. , Barreto, W.G. , Corradini, P. , Min, C.‐K. , Medvedova, E. , Thiyagarajah, P. , Deraedt, W. , Chiu, C. , Schecter, J. & Weisel, K.C. (2017) Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of CASTOR. Blood, 130, 3145.

3- Reeder, C.B. , Reece, D.E. , Kukreti, V. , Mikhael, J.R. , Chen, C. , Trudel, S. , Laumann, K. , Vohra, H. , Fonseca, R. , Bergsagel, P.L. , Leis, J.F. , Tiedemann, R. & Stewart, A.K. (2014) Long‐term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 167, 563–565.

4- Ocio, E.M. ,Richardson, P.G. ,Rajkumar, S.V. , Palumbo, A. , Mateos, M.V. , Orlowski, R. , Kumar, S. , Usmani, S. , Roodman, D. , Niesvizky, R. , Einsele, H. , Anderson, K.C. , Dimopoulos, M.A. , Avet‐Loiseau, H. , Mellqvist, U.H. , Turesson, I. , Merlini, G. , Schots, R. , McCarthy, P. , Bergsagel, L. , Chim, C.S. , Lahuerta, J.J. , Shah, J. , Reiman, A. , Mikhael, J. , Zweegman, S. , Lonial, S. , Comenzo, R. , Chng, W.J. , Moreau, P. , Sonneveld, P. , Ludwig, H. , Durie, B.G. & Miguel, J.F. (2014) New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia, 28, 525–542.

5- Kumar, S. , Paiva, B. , Anderson, K.C. , Durie, B. , Landgren, O. , Moreau, P. , Munshi, N. , Lonial, S. , Blade, J. , Mateos, M.‐V. , Dimopolous, M. , Kastritis, E. , Boccadoro, M. , Orlowski, R. , Goldschmidt, H. , Spencer, A. , Hou, J. , Chng, W.J. , Usmani, S. , Zagmani, E. , Shimizu, K. , Jagannath, S. , Johnsen, H.E. , Terpos, E. , Reiman, A. , Kyle, R.A. , Sonneveld, P. , Richardson, P.G. , McCarthy, P. , Ludwig, H. , Chen, W. , Cavo, M. , Harousseau, J.L. , Lentzsch, S. , Hillengass, J. , Palumbo, A. , Orfao, A. , Rajkumar, S.V. , San Miguel, J. & Avet‐Loiseau, H. (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, 17, e328–e346.

6- Kurtin, S.E. (2013) Relapsed or relapsed/refractory multiple myeloma. Journal of the Advanced Practitioner in Oncology, 4, 5–14.

7- Lonial, S. , San‐Miguel, J.F. , Martínez‐Lopez, J. , Mateos, M.‐V. , Blade, J. , Benboubker, L, Oriol, A. , Arnulf, B. , Chari, A. , Pineiro, L., Wu, K. , Wang, J. , Doshi, P. , Schecter, J. & Moreau, P. (2017) Daratumumab in combination with carfilzomib and dexamethasone in patients (pts) with relapsed multiple myeloma (MMY1001): an open‐label, phase 1b study. Blood, 130, 1869.

8-Mai, E.K. , Bertsch, U. , Durig, J. , Kunz, C. , Haenel, M. , Blau, I.W. , Munder, M. , Jauch, A. , Schurich, B. , Hielscher, T. , Merz, M. , Huegle‐Doerr, B. , Seckinger, A. , Hose, D. , Hillengass, J. , Raab, M.S. , Neben, K. , Lindemann, H.W. , Zeis, M. , Gerecke, C. , Schmidt‐Wolf, I.G., Weisel, K. , Scheid, C. , Salwender, H. & Goldschmidt, H. (2015) Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia, 29, 1721–1729.